Requestioning depression in patients with cancer: Contribution of somatic and affective symptoms to Beck's Depression Inventory

Wedding, Ulrich; Koch, A.; Röhrig, Bernd; Pientka, Ludger; Sauer, Heinrich; Höffken, K.; Maurer, Iris

doi:10.1093/annonc/mdm353

Cited by 40 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Somatic symptoms are extremely common among populations with different types of cancer and may potentially be an expression of both depression and/ or the underlying neoplasm 25 . However, in spite of the fact that fatigue and weight loss/gain are more frequently reported by women with ovarian cancer during advanced (stages III-IV) versus early (stages I-II) stages, the onset of these symptoms may begin up to 2-7 months prior to diagnosis, suggesting that these manifestations may result from shared mechanisms that also drive tumorigenesis 26 .…”

Section: Epidemiological Links Between Depression and Cancermentioning

confidence: 99%

Depression in cancer: The many biobehavioral pathways driving tumor progression

Bortolato

Hyphantis

Valpione

et al. 2017

Cancer Treatment Reviews

261

179

View full text Add to dashboard Cite

Major Depressive Disorder (MDD) is common among cancer patients, with prevalence rates up to four-times higher than the general population. Depression confers worse outcomes, including non-adherence to treatment and increased mortality in the oncology setting. Advances in the understanding of neurobiological underpinnings of depression have revealed shared biobehavioral mechanisms may contribute to cancer progression. Moreover, psychosocial stressors in cancer promote:(1) inflammation and oxidative/nitrosative stress; (2) a decreased immunosurveillance; and (3) a dysfunctional activation of the autonomic nervous system and of the hypothalamic-pituitary-adrenal axis. Consequently, the prompt recognition of depression among patients with cancer who may benefit of treatment strategies targeting depressive symptoms, cognitive dysfunction, fatigue and sleep disturbances, is a public health priority. Moreover, behavioral strategies aiming at reducing psychological distress and depressive symptoms, including addressing unhealthy diet and life-style choices, as well as physical inactivity and sleep dysfunction, may represent important strategies not only to treat depression, but also to improve wider cancer-related outcomes. Herein, we provide a comprehensive review of the intertwined biobehavioural pathways linking depression to cancer progression. In addition, the clinical implications of these findings are critically reviewed.

show abstract

Section: Epidemiological Links Between Depression and Cancermentioning

confidence: 99%

Depression in cancer: The many biobehavioral pathways driving tumor progression

Bortolato

Hyphantis

Valpione

et al. 2017

Cancer Treatment Reviews

261

179

View full text Add to dashboard Cite

show abstract

“…Depresyon varlığını ve şiddetini literatürde yaygın olarak kullanılan BDÖ ile değerlendirdik. [7] Bu ölçek psikiyatrik hastaları değerlendirmek için Beck ve ark. tarafından geliştirilmiştir.…”

Section: Discussionunclassified

“…tarafından yapılmıştır. [7,10] Depresyon şiddetini belirlemede kanser hastalarında da yaygın olarak kullanılmakta olup, 21 sorudan oluşan bir ankettir.…”

Section: Discussionunclassified

“…Depresyon puanı 1-9 arası yok, 10-16 arası hafif, 17-23 arası orta ve ≥24 ciddi depresyon olarak sınıflandırıl-dı. [7] BDÖ için 10 cut-off değeri olarak alınıp, hastalar depresyon puanı ≤10 ve >10 olarak sınıflandırılarak, psikiyatrik destek gereksinimine göre gruplandırıldı. Depresyon puanı 10 ve üzeri olanlar için psikiyatrik yardım önerildi.…”

Section: Hastalar Ve Yöntemunclassified

“…[5,6] Depresyon tanısında çeşitli anket formları, klinik diyaloglar veya özet tarama programları kullanılmış olup, en sık kullanılan tarama testi Beck Depresyon Ölçeği-dir (BDÖ). [7] BDÖ ile tanının konulması yanında depresyon şiddeti de ölçülebilir, buna göre hastanın psikiyatrik desteğe ihtiyacı olup olmadığı belirlenir.…”

Section: Introductionunclassified

See 2 more Smart Citations

Depression Analysis in Patients Treated with Chemotherapy: Single Center Experience

Ustaalıoğlu¹,

Öztürk²,

Er³

et al. 2014

J Kartal TR

View full text Add to dashboard Cite

ÖzetAmaç: Kanserli hastalarda depresyon en sık görülen psikiyatrik sorundur. Depresyonun erken tanı ve tedavisi, hastaların tedaviye uyumunu ve yaşam kalitesini artıracaktır. Biz kemoterapi alan hastalarımızda depresyon varlığı ve psikiyatrik destek gereksinimini değerlendirdik.Gereç ve Yöntem: Çalışmamızda, kemoterapi ünitemizde tedavi almak için gelen 155 hastayı değerlendirdik. Hastaların depresyon varlığını ve düzeyini belirlemek için Beck Depresyon Ölçeği (BDÖ) kullandık. Hastaların kişisel ve klinik özel-likleriyle psikiyatrik destek gereksinimi arasındaki ilişkilerini ki-kare testi ile değerlendirdik. Bulgular:Hastalarımızın yaş ortalaması 58 (21-78) idi. Hastalarımızın 61.9%'u erkek olup, çoğunluğu emekli idi. BDÖ'ye göre ortanca depresyon puanı 9 (0-41) olarak bulundu. Depresyon sınıflaması; %10.3 (n=16) ciddi, %10.3 (n=16) orta, %27.1 (n=42) hafif depresyondu. Geriye kalan 81 hastada (%52.3) depresyon saptanmadı. Metastaz varlığı ve aldığı kemoterapi şekli ve progresyon varlığı psikiyatrik tedavi gereksinimi ile ilişkili olarak bulundu (p<0.05).Sonuç: Kanserli hastalarda depresyonun tanısı ve derecelendirmesi ile hastaya uygun psikiyatrik desteğin sağlan-ması kanser tedavisinin bir parçasıdır. Bu süreçte hastalara psikososyal destek sağlamak kemoterapi ünitesi ve onkoloji çalışanları için bir görev olmalıdır.

show abstract

Depressive Symptom Dimensions and Cardiovascular Prognosis Among Women With Suspected Myocardial Ischemia

Linke

Rutledge²,

Johnson³

et al. 2009

Arch Gen Psychiatry

114

View full text Add to dashboard Cite

Context: Symptoms of depression and cardiovascular disease overlap substantially. Differentiating between dimensions of depressive symptoms may improve our understanding of the relationship between depression and physical health. Objective: To compare symptom dimensions of depression as predictors of cardiovascular-related death and events among women with suspected myocardial ischemia. Design: Cohort study of women with suspected myocardial ischemia who were evaluated at baseline for history of cardiovascular-related problems, depressive symptoms using the Beck Depression Inventory (BDI), and coronary artery disease severity via coronary angiogram. Principal components analyses (PCA) of the BDI items were conducted to examine differential cardiovascular prognosis according to symptom dimensions of depression. Setting: The Women's Ischemia Syndrome Evaluation (WISE), a National Heart, Lung, and Blood Institute (NHLBI)–sponsored multi-center study assessing cardiovascular function using state-of-the-art techniques in women referred for coronary angiography to evaluate chest pain or suspected myocardial ischemia. Participants: 550 women (mean age = 58.4 [11.2] years) enrolled in WISE and followed for a median of 5.8 years. Main Outcome Measures: Cardiovascular-related mortality and events (stroke, myocardial infarction, and congestive heart failure). Results: Using a three-factor structure from PCA, somatic/affective (hazards ratio [HR]=1.35, 95% confidence interval [CI]=1.04-1.74) and appetitive (HR=1.42, 95%CI=1.21-1.68) but not cognitive/affective (HR=.89, 95%CI=.70-1.14) symptoms predicted cardiovascular prognosis in adjusted multivariate Cox regression analysis. Using a two-factor structure from PCA, adjusted results indicated that somatic (HR=1.63, 95% CI=1.28-2.08) but not cognitive/affective (HR=.87, 95% CI=.68-1.11) symptoms predicted worse prognosis. Conclusions: In a sample of women with suspected myocardial ischemia, somatic but not cognitive/affective depressive symptoms were associated with an increased risk of cardiovascular-related mortality and events. These results support the need to research dimensions of depression in CVD populations and have implications for understanding the connection between depression and CVD. Unstructured Abstract Differentiating between dimensions of depressive symptoms may improve our understanding of the relationship between depression and cardiovascular disease (CVD). This study examined depressive symptom dimensions as predictors of cardiovascular-related death and events among women undergoing coronary angiography to evaluate suspected myocardial ischemia (n=550; mean age=58.4 [11.2] years). Baseline evaluation included depressive symptom assessment using the Beck Depression Inventory (BDI) and coronary artery disease severity testing via coronary angiogram. Incidence of the women's cardiovascular-related mortality and events (stroke, myocardial infarction, and congestive heart failure) was tracked for a median of 5.8 years. Principal components an...

show abstract

Requestioning depression in patients with cancer: Contribution of somatic and affective symptoms to Beck's Depression Inventory

Abstract: Most alterations in the BDI in cancer patients are related to somatic and not to affective symptoms and may be attributed not to depression but to severity of the underlying disease.

Cited by 40 publications

References 31 publications

Depression in cancer: The many biobehavioral pathways driving tumor progression

Depression in cancer: The many biobehavioral pathways driving tumor progression

Depression Analysis in Patients Treated with Chemotherapy: Single Center Experience

Depressive Symptom Dimensions and Cardiovascular Prognosis Among Women With Suspected Myocardial Ischemia

Contact Info

Product

Resources

About